Insider · CIK 0001355415

Clark William D

Reports to the SEC for 5 companies · LEXINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001355415

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-09	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+2,323 sh	—	—	2,323
2026-06-09	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+70K sh	—	—	70,000
2025-11-20	IBIOiBio, Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.5K sh	—	—	13,500
2025-04-17	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+76.8K sh	—	—	76,760
2025-01-10	IBIOiBio, Inc.P Purchase	Director	PPurchase	+1,838 sh	$2.72	+$4,999.36	1,838
2024-11-21	IBIOiBio, Inc. · Stock Option (right to buy)A Award	Director	AAward	+18.9K sh	—	—	18,900
2022-06-02	GENOCEA BIOSCIENCES, INC.S Sale	Director, President and CEO	SSale	−4,023 sh	$0.06	−$241.38	304,377
2022-05-31	GENOCEA BIOSCIENCES, INC.S Sale	Director, President and CEO	SSale	−117K sh	$0.06	−$7,233.955	308,400
2022-04-04	GENOCEA BIOSCIENCES, INC.S Sale	Director, President and CEO	SSale	−3,924 sh	$1.25	−$4,905	369,487
2022-03-16	GENOCEA BIOSCIENCES, INC.S Sale	Director, President and CEO	SSale	−11.4K sh	$1.10	−$12.6K	373,411
2022-03-15	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+450K sh	—	—	450,000
2022-03-15	GENOCEA BIOSCIENCES, INC.A Award	Director, President and CEO	AAward	+150K sh	—	—	384,846
2021-12-09	IBIOiBio, Inc. · Stock Option (right to buy)A Award	Director	AAward	+109K sh	—	—	109,000
2021-08-23	IBIOiBio, Inc. · Stock Option (right to buy)A Award	Director	AAward	+100K sh	—	—	100,000
2021-06-01	GENOCEA BIOSCIENCES, INC.S Sale	Director, President and CEO	SSale	−2,080 sh	$2.23	−$4,638.4	286,003
2021-04-02	GENOCEA BIOSCIENCES, INC.S Sale	Director, President and CEO	SSale	−3,794 sh	$2.71	−$10.3K	288,083
2021-03-15	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+450K sh	—	—	450,000
2021-03-15	GENOCEA BIOSCIENCES, INC.Restricted Stock UnitA Award	Director, President and CEO	AAward	+600K sh	—	—	600,000
2021-03-15	GENOCEA BIOSCIENCES, INC.A Award	Director, President and CEO	AAward	+150K sh	—	—	150,000
2021-02-17	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−16.5K sh	—	—	171,000
2021-02-17	GENOCEA BIOSCIENCES, INC.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+20K sh	$2.72	+$54.4K	63,750
2021-02-17	GENOCEA BIOSCIENCES, INC.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+16.5K sh	$1.66	+$27.4K	43,752
2021-02-17	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−20K sh	—	—	86,690
2020-11-10	GENOCEA BIOSCIENCES, INC.P Purchase	Director, President and CEO	PPurchase	+4,760 sh	$2.06	+$9,805.6	4,760
2020-06-01	GENOCEA BIOSCIENCES, INC.A Award	Director, President and CEO	AAward	+27.3K sh	—	—	27,344
2020-06-01	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+107K sh	—	—	106,688
2020-04-02	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+188K sh	—	—	187,500
2020-04-02	GENOCEA BIOSCIENCES, INC.A Award	Director, President and CEO	AAward	+50.8K sh	—	—	50,783
2019-03-15	GENOCEA BIOSCIENCES, INC.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+15K sh	$0.54	+$8,100	119,931
2019-03-15	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−15K sh	—	—	735,000
2019-02-07	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+750K sh	—	—	750,000
2018-06-21	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+468K sh	—	—	864,000
2018-06-05	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2018-02-08	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+396K sh	—	—	396,000
2018-01-17	GENOCEA BIOSCIENCES, INC.P Purchase	Director, President and CEO	PPurchase	+25K sh	$0.80	+$20K	82,931
2017-11-15	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Director	AAward	+7,324 sh	—	—	7,324
2017-11-15	XFORX4 Pharmaceuticals, Inc · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2017-02-28	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+288K sh	—	—	288,000
2016-11-07	GENOCEA BIOSCIENCES, INC.P Purchase	Director, President and CEO	PPurchase	+2,800 sh	$3.49	+$9,772	52,205
2016-02-02	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+288K sh	—	—	288,000
2015-12-16	GENOCEA BIOSCIENCES, INC.P Purchase	Director, President and CEO	PPurchase	+3,800 sh	$6.45	+$24.5K	43,607
2015-02-26	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+138K sh	—	—	138,000
2014-12-12	GENOCEA BIOSCIENCES, INC.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+19.8K sh	$2.86	+$56.6K	39,807
2014-12-12	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−19.8K sh	—	—	0
2014-09-02	GENOCEA BIOSCIENCES, INC.Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−20K sh	—	—	19,807
2014-09-02	GENOCEA BIOSCIENCES, INC.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+20K sh	$2.86	+$57.2K	20,000
2014-02-10	GENOCEA BIOSCIENCES, INC.Option to purchase Common StockA Award	Director, President and CEO	AAward	+81.7K sh	—	—	81,670
2010-02-19	VNDAVanda Pharmaceuticals Inc.S Sale	Sr. VP, Chief Business Officer	SSale	−9,522 sh	$10.65	−$101K	168,279
2010-02-18	VNDAVanda Pharmaceuticals Inc.M Exercise/Conversion	Sr. VP, Chief Business Officer	MExercise/Conversion	+25K sh	—	—	177,801
2010-02-18	VNDAVanda Pharmaceuticals Inc. · Restricted Stock UnitsM Exercise/Conversion	Sr. VP, Chief Business Officer	MExercise/Conversion	−25K sh	—	—	0

Recent filings

Accepted (ET)
Jun 114
Clark William D0001193125-26-267611
SEC(opens sec.gov)
Nov 244
Clark William D0001104659-25-115411
SEC(opens sec.gov)
Apr 184
Clark William D0000950170-25-055900
SEC(opens sec.gov)
Jan 134
Clark William D0001104659-25-003060
SEC(opens sec.gov)
Nov 254
Clark William D0001104659-24-122590
SEC(opens sec.gov)
Jun 34
Clark William D0001457612-22-000073
SEC(opens sec.gov)
Jun 24
Clark William D0001457612-22-000069
SEC(opens sec.gov)
Apr 54
Clark William D0001457612-22-000043
SEC(opens sec.gov)
Mar 174
Clark William D0001457612-22-000026
SEC(opens sec.gov)
Mar 165
Clark William D0001457612-22-000016
SEC(opens sec.gov)
Dec 134
Clark William D0001104659-21-149239
SEC(opens sec.gov)
Aug 254
Clark William D0001104659-21-109466
SEC(opens sec.gov)
Mar 174
Clark William D0001457612-21-000040
SEC(opens sec.gov)
Feb 184
Clark William D0001457612-21-000016
SEC(opens sec.gov)

Companies

Address

C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE

LEXINGTON, MA, 02421